Uniqure NV
QURE · NASDAQ
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
Market Data
Price
$18.26
+0.27 (+1.50%)
Market Cap$1.14B
P/E Ratio—
EPS$—
52W High$71.50
52W Low$7.76
Beta0.73
Data from Finnhub · Updated Mar 11, 2026